Holen Sie sich die Stockscreener-App
0.9365
1.50%
-0.0143
Handel nachbörslich:
.93
-0.0065
-0.69%
Schlusskurs vom Vortag:
$0.9508
Offen:
$0.98
24-Stunden-Volumen:
536.75K
Relative Volume:
0.54
Marktkapitalisierung:
$89.06M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-19.58M
KGV:
-3.6341
EPS:
-0.2577
Netto-Cashflow:
$-20.25M
1W Leistung:
-9.95%
1M Leistung:
-9.08%
6M Leistung:
-15.63%
1J Leistung:
-25.67%
1-Tages-Spanne:
$0.9335
$0.98
1-Wochen-Bereich:
$0.93
$1.075
52-Wochen-Spanne:
$0.5501
$2.05
Cognition Therapeutics Inc Stock (CGTX) Company Profile
Firmenname
Cognition Therapeutics Inc
Sektor
Branche
Telefon
412-481-2210
Adresse
2500 WESTCHESTER AVE, PURCHASE
Compare CGTX vs VRTX, REGN, MRNA, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CGTX
Cognition Therapeutics Inc
|
0.9365 | 89.06M | 0 | -19.58M | -20.25M | -0.2577 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cognition Therapeutics Inc Stock (CGTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-19 | Hochstufung | B. Riley Securities | Neutral → Buy |
| 2024-07-30 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2021-11-03 | Eingeleitet | B. Riley Securities | Buy |
| 2021-11-03 | Eingeleitet | Oppenheimer | Outperform |
Cognition Therapeutics Inc Aktie (CGTX) Neueste Nachrichten
H.C. Wainwright Maintains Cognition Therapeutics(CGTX.US) With Buy Rating, Maintains Target Price $3 - Moomoo
Cognition Therapeutics, Inc.Common Stock (Nasdaq:CGTX) Detailed Stock Data - The Chronicle-Journal
CGTX News | COGNITION THERAPEUTICS INC (NASDAQ:CGTX) - ChartMill
MU: Micron Technology Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
FDA aligns with Cognition on pivotal DLB psychosis trial - scanx.trade
An Alzheimer's drug will be discussed Sept. 15 by Cognition Therapeutics - Stock Titan
CGTX Q2 2026 Earnings: Narrower-Than-Expected Loss Provides Positive Surprise, Shares SlipFinancial Health Score - dars.gov.et
Cognition Therapeutics Inc (CGTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Cognition (CGTX) Today: Moves 1.14% Lower to $0.98 for the Current Session; Technical Setup: the $0.93 to $1.03 Range Remains in Focus under the Current SnapshotIPO Entry Watch - vinanet.vn
Cognition (CGTX) Earnings Report: Reported EPS Tops Expectations; Market Reaction: Shares Move 0.22% Lower in the Latest ReadingPreliminary Results - vinanet.vn
Cognition Therapeutics Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Cognition (CGTX) Close in Focus: Ends Down by 3.33% at $0.99; Chart Reference: Price Remains Between $0.94 Support and $1.04 Resistance in the Current UpdateOpening Range Breakout - careplusvn.com
HC Wainwright Has Bullish Estimate for CGTX Q3 Earnings - MarketBeat
Cognition Therapeutics (CGTX) Slips 2.9% to $1.01, Nears Support at $0.96Dealer Delta - vinanet.vn
Cognition Therapeutics (NASDAQ:CGTX) Stock Rating Lowered by Wall Street Zen - MarketBeat
CGTX FY2026 EPS Forecast Raised by Brookline Capital Markets - MarketBeat
Cognition Therapeutics Inc (CGTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cognition Therapeutics Inc (CGTX) Stock News Today - TradingKey
Cognition Therapeutics Stock (CGTX) Opinions on biotech upside speculation - Quiver Quantitative
Cognition Therapeutics (NASDAQ:CGTX) Releases Earnings Results, Beats Estimates By $0.02 EPS - MarketBeat
Cognition Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Cognition Therapeutics, Inc. (CGTX) latest stock news and headlines - Yahoo Finance UK
Cognition Therapeutics Inc Q2 2026: Net loss $(3.9M), EPS $(0.04) — 10-Q Summary - TradingView
Cognition Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Cognition Therapeutics Q2 EPS beats estimate as R&D cuts narrow losses - scanx.trade
Cognition Therapeutics, Inc. (CGTX) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Cognition Therapeutics reports Q2 2026 net loss $3.9M, cash $34.8M; plans Phase 3 in DLB psychosis - TradingView
Cognition Therapeutics Q2 net loss narrows on lower R&D costs - TradingView
Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update - Yahoo Finance
Cognition Therapeutics Inc expected to post a loss of 6 cents a shareEarnings Preview - TradingView
Cognition Therapeutics (CGTX) Edges Higher as Traders Eye Key Resistance LevelsBearish Sentiment - careplusvn.com
Cognition Therapeutics (NASDAQ:CGTX) Trading Up 3.3%Time to Buy? - MarketBeat
Cognition Therapeutics Inc (CGTX) Balance Sheet - TradingKey
CGTX|Cognition Therapeutics Inc|Price:1.020|Chg%:-0.040 - tradingkey.com
Cognition Therapeutics Inc (CGTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Cognition Therapeutics Inc (CGTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cognition Therapeutics Inc (CGTX) Cash Flow - TradingKey
Cognition Therapeutics Inc (CGTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Cognition Therapeutics Inc (CGTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
CGTX|Cognition Therapeutics Inc|Price:0.919|Chg%:-0.041 - TradingKey
Cognition Therapeutics Inc (CGTX) Income Statement - TradingKey
Cognition Therapeutics, Inc. Revenue Breakdown – NASDAQ:CGTX - TradingView
CGTX|Cognition Therapeutics Inc|Price:0.982|Chg%:-0.038 - TradingKey
CGTX Q1 2026 Earnings: Narrower-Than-Expected Loss Signals Progress in Alzheimer’s PipelineSlow Growth Warning - dars.gov.et
Cognition Therapeutics (CGTX) Slips 4% as Support Level Comes Into FocusBreakout Confirmation - dars.gov.et
Cognition Therapeutics (CGTX) Q2 2024 earnings summary - Quartr
CGTX Q1 2026 Earnings: Narrower Loss Bolsters Cash Runway as Alzheimer’s Trials ContinueGuidance Revision Trend - vinanet.vn
CGTX Q1 2026 Earnings: Narrower-than-expected loss as clinical pipeline advancesEarnings Power Value - careplusvn.com
Cognition Therapeutics (CGTX) Edges Higher as Biotech Stock Tests Key ResistanceAnalyst Upgrade Stocks - dars.gov.et
Is Cognition Therapeutics (NASDAQ:CGTX) In A Good Position To Invest In Growth? - Sahm
Cognition Therapeutics (CGTX) Edges Lower as Stock Hovers Near Key Support LevelRVOL Breakout - dars.gov.et
Finanzdaten der Cognition Therapeutics Inc-Aktie (CGTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.06%
2.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):